A case of primary malignant melanoma of the lung responded to anti-PD-1 antibody therapy
- 9 March 2017
- journal article
- case report
- Published by Springer Science and Business Media LLC in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (2), 173-175
- https://doi.org/10.1007/s12055-017-0488-z
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary CancersPLOS ONE, 2015
- Immune Checkpoint Blockade in Cancer TherapyJournal of Clinical Oncology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationThe New England Journal of Medicine, 2015
- Control of CD8 T-Cell Infiltration into Tumors by Vasculature and MicroenvironmentPublished by Elsevier BV ,2015
- Primary pulmonary malignant melanoma: a clinicopathologic study of two casesDiagnostic Pathology, 2012
- Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic MelanomaCancer Research, 2012
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 2002
- Primary Melanoma of the Lung: A Clinicopathologic and Immunohistochemical Study of Eight CasesThe American Journal of Surgical Pathology, 1997